Group 1 - Xianghe Industrial signed a contract worth 43.1041 million yuan with China Railway 15th Bureau, accounting for approximately 6.5% of the company's projected revenue for 2024 [1] - Dayu Water-saving's subsidiary won a bid for a project valued at 133 million yuan, with a construction period of 545 days [2] - China National Materials International's subsidiary signed a contract worth 299 million Canadian dollars for engineering design and procurement services [3] Group 2 - Baoland expects a net loss of approximately 75 million yuan for 2025, compared to a loss of 58.7224 million yuan in the previous year [4] - Changhong High-tech received an administrative regulatory decision due to inadequate internal controls and improper revenue recognition [5] - Debon Stock will be suspended from trading on January 21, 2026, pending a decision on its delisting [6] Group 3 - Haitai Technology anticipates a net profit increase of 226.86% to 323.97% for 2025, with an expected profit of 51.5 million to 66.8 million yuan [7] - Fushun Special Steel expects a net loss of 770 million to 870 million yuan for 2025, compared to a profit of 112 million yuan in the previous year [8] - Rejing Bio forecasts a net loss of 210 million to 230 million yuan for 2025, compared to a loss of 191 million yuan in the previous year [10] Group 4 - Sanyou Chemical expects a net profit of approximately 91 million yuan for 2025, a decrease of about 82% compared to the previous year [11] - Lianhuan Pharmaceutical received approval for clinical trials of a new drug for benign prostatic hyperplasia [12] - Samsung New Materials anticipates a net loss for 2025, indicating a decline in operational performance [13] Group 5 - Jinggong Technology expects a net profit increase of 36.1% to 70.13% for 2025, with an estimated profit of 200 million to 250 million yuan [14] - Zhongsheng Pharmaceutical's subsidiary signed a licensing agreement for the production and commercialization of RAY1225 injection, with total payments expected to reach 1 billion yuan [15] - Hengshuai shares saw a reduction of 600,000 convertible bonds held by its controlling shareholder [16] Group 6 - Buchang Pharmaceutical plans to repurchase shares worth 60 million to 120 million yuan for employee stock ownership plans [17] - Baike Bio expects a net loss of 220 million to 280 million yuan for 2025, marking a shift from profit to loss [18] - Weishi Electronics anticipates a net profit decrease of 53.27% to 61.61% for 2025, with expected profits of 21.49 million to 26.16 million yuan [19] Group 7 - China Automotive Research expects a net profit increase of 17.85% for 2025, with a projected profit of 1.06 billion yuan [20] - Hualan Biological's controlling shareholder raised the upper limit of its shareholding plan to 86.66 yuan per share [22] - Nasda anticipates a net loss for 2025, indicating a decline in financial performance [23] Group 8 - Haizheng Pharmaceutical received a warning letter from the Zhejiang Securities Regulatory Commission for financial data inaccuracies [24] - Mengguli received an administrative regulatory decision for accounting errors in its financial reports [25] - Zhongguancun's subsidiary received acceptance for a drug application for a heart-related treatment [26] Group 9 - Hosheng Silicon Industry was ordered to correct information disclosure violations by the Zhejiang Securities Regulatory Commission [27] - Meiteng Technology expects a net profit decrease of 22.4551 million to 28.5285 million yuan for 2025, a reduction of 55.21% to 70.14% [28] - Sanwei Co. received a warning letter for financial irregularities related to related party transactions [29] Group 10 - Ganyue Expressway expects a net profit increase of 3.18% for 2025, with a projected profit of 1.32 billion yuan [30] - Xinhang New Materials plans to acquire 51% of Hairete for 12.8826 million yuan [31] - China Software anticipates a net loss of 41 million to 49 million yuan for 2025, an improvement from the previous year's loss [32] Group 11 - Rongsheng Development expects a net loss for 2025, with losses not exceeding the previous year's audited net assets [33] - Northern Rare Earth anticipates a net profit increase of 117% to 135% for 2025, with expected profits of 2.176 billion to 2.356 billion yuan [34] - Energy-saving Wind Power received renewable energy subsidies totaling 1.507 billion yuan, a 122.74% increase from the previous year [35] Group 12 - Dongzhu Ecology expects a net loss of 935 million to 1.135 billion yuan for 2025, compared to a loss of 630 million yuan in the previous year [36] - Jingneng Real Estate anticipates a net loss of 986 million to 1.315 billion yuan for 2025, compared to a loss of 109 million yuan in the previous year [37] - Hailu Heavy Industry signed new orders worth 1.941 billion yuan for 2025, with total orders on hand amounting to 3.597 billion yuan [38] Group 13 - Dalian Thermal Power expects a net loss of 92 million to 112 million yuan for 2025, compared to a loss of 146 million yuan in the previous year [39] - Jiangsu Sop expects a net profit decrease of 52.99% to 62.4% for 2025, with profits projected between 8 million to 10 million yuan [40] - Lian Technology plans to initiate preparations for issuing H-shares and listing on the Hong Kong Stock Exchange [42] Group 14 - Zhenyang Development expects a net profit decrease of 58.13% to 64.94% for 2025, with profits projected between 67 million to 80 million yuan [43] - Sheneng Co. reported a 1.7% decrease in power generation for 2025, with total generation of 57.654 billion kWh [44] - XGIMI Technology's subsidiary received a development notification from a well-known domestic automotive manufacturer [45] Group 15 - Wanhua Chemical's MDI Phase II facility resumed production after maintenance [46] - Daqing Energy expects a net loss of 1 billion to 1.3 billion yuan for 2025, with a reduction in losses compared to the previous year [47]

报告期内，受益于行业较高景气度及公司首发募投项目产能逐渐释放，公司订单持续增加，驱动营业收 入保持稳健增长，利润水平同步提升。公司持续深化成本管控，进一步增强了整体盈利能力。此外，受 提前赎回前期发行的可转换公司债券使有息负债规模较上年同期大幅减少、欧元汇率升值带来汇兑收益 因素影响，利润增长形成正向支撑。综上，公司经营业绩延续良好增长态势。 海泰科（301022）(301022.SZ)发布2025年度业绩预告，预计全年实现归属于上市公司股东的净利润 5,150万元至6,680万元，同比增长226.86%-323.97%。 ...

Core Viewpoint - The company, Haitai Technology (301022.SZ), forecasts a net profit attributable to shareholders for the year 2025 in the range of 51.5 million to 66.8 million yuan, representing a year-on-year growth of 226.86% to 323.97% [1] Group 1: Financial Performance - The company benefits from a high industry prosperity and the gradual release of capacity from its initial public offering investment projects, leading to a continuous increase in orders [1] - The company's operating revenue maintains steady growth, which drives an improvement in profit levels [1] - Enhanced cost control measures have further strengthened the overall profitability of the company [1] Group 2: External Factors - The early redemption of previously issued convertible bonds has significantly reduced the scale of interest-bearing liabilities compared to the same period last year [1] - The appreciation of the euro has resulted in foreign exchange gains, providing positive support for profit growth [1]

Core Viewpoint - The company expects a net profit of 51.5 million to 66.8 million yuan for the fiscal year 2025, representing a year-on-year growth of 226.86% to 323.97% [1] Group 1: Financial Performance - The increase in net profit is driven by a high industry prosperity and the gradual release of production capacity from the company's initial public offering projects, leading to a continuous increase in orders [1] - The company's operating revenue is expected to maintain steady growth, with profit levels also improving correspondingly [1] Group 2: Cost Management and Financial Strategy - The company has been deepening cost control measures, which have further enhanced overall profitability [1] - A significant reduction in interest-bearing liabilities compared to the previous year, due to the early redemption of previously issued convertible bonds, has positively supported profit growth [1] - The appreciation of the euro has resulted in foreign exchange gains, contributing to the profit increase [1]

格隆汇1月16日丨海泰科(301022.SZ)公布，预计2025年归属于上市公司股东的净利润5,150万元～6,680 万元，比上年同期增长226.86%～323.97%，扣除非经常性损益后的净利润3,700万元～4,800万元，比上 年同期增长353.30%～488.06%。 报告期内，受益于行业较高景气度及公司首发募投项目产能逐渐释放，公司订单持续增加，驱动营业收 入保持稳健增长，利润水平同步提升。公司持续深化成本管控，进一步增强了整体盈利能力。此外，受 提前赎回前期发行的可转换公司债券使有息负债规模较上年同期大幅减少、欧元汇率升值带来汇兑收益 因素影响，利润增长形成正向支撑。综上，公司经营业绩延续良好增长态势。 ...

海泰科公告，预计2025年度净利润为5150万元到6680万元，同比增长226.86%到323.97%。报告期内， 受益于行业较高景气度及公司首发募投项目产能逐渐释放，公司订单持续增加，驱动营业收入保持稳健 增长，利润水平同步提升。公司持续深化成本管控，进一步增强了整体盈利能力。此外，受提前赎回前 期发行的可转换公司债券使有息负债规模较上年同期大幅减少、欧元汇率升值带来汇兑收益因素影响， 利润增长形成正向支撑。 ...

证券代码：301022 证券简称：海泰科 公告编号：2026-004 青岛海泰科模塑科技股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 2、业绩预告情况：预计净利润为正值且属于同向上升 50%以上情形 （1）以区间数进行业绩预告的 单位：万元 | 项 目 | 本报告期 | | | | 上年同期 | | --- | --- | --- | --- | --- | --- | | 归属于上市公司 | | 5,150 | ～ | 6,680 | 1,575.60 | | 股东的净利润 | 比上年同期增长 | 226.86% | ～ | 323.97% | | | 扣除非经常性损 | | 3,700 | ～ | 4,800 | 816.24 | | 益后的净利润 | 比上年同期增长 | 353.30% | ～ | 488.06% | | 二、与会计师事务所沟通情况 本次业绩预告中的财务数据未经注册会计师审计。公司已就本次业绩 ...

证券代码：301022 证券简称：海泰科 公告编号：2026-003 青岛海泰科模塑科技股份有限公司 关于使用暂时闲置募集资金进行现金管理到期赎回并继续进行现 金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 二、本次使用暂时闲置募集资金进行现金管理的进展情况 | 序 | 购买主 | 签约银行 | 产品名 | 产品类型 | 认购金 | 起息 | 到期 | 预期年化 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 号 | 体 | | 称 | | 额（元） | 日 | 日 | 收益率 | | | 海泰科 | 青岛银行股份有限 | 结构性 | 保本浮动 | 57,000,0 | 2026. | 2026. | 1.20%-1. | | 1 | 模塑 | 公司辽宁路支行 | 存款 | 收益型 | 00.00 | 01.15 | 03.04 | 95% | 三、审议程序 青岛海泰科模塑科技股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日 召开了第二届董事会第二十九次 ...

证券代码：301022 证券简称：海泰科 公告编号：2026-002 青岛海泰科模塑科技股份有限公司 关于使用暂时闲置募集资金进行现金管理到期赎回并继续进行现 金管理的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 青岛海泰科模塑科技股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日 召开了第二届董事会第二十九次会议、第二届监事会第二十四次会议，审议通过了 《关于使用暂时闲置募集资金及自有资金进行现金管理的议案》，同意公司及全资 子公司在确保不影响募集资金投资项目建设、不影响正常生产经营及确保资金安全 的情况下，使用不超过人民币 35,000.00 万元的暂时闲置募集资金和不超过人民币 10,000.00 万元的自有资金进行现金管理，使用期限自董事会审议通过之日起 12 个 月内有效，上述额度可以由公司使用，亦可以由公司的全资子公司使用，但应予以 合并计算。本次额度生效后将覆盖前次授权额度，在前述额度和期限范围内，资金 可循环滚动使用。本事项在董事会审议权限范围内，无需提交公司股东会审议。具 体详见公司于 2025 年 4 月 24 ...

证券日报网讯 1月7日，海泰科在互动平台回答投资者提问时表示，公司严格按照相关法律、法规履行 信息披露义务，不存在应披露而未披露的重大事项。公司不会也无法操纵市场！敬请投资者理性投资并 注意投资风险。 （文章来源：证券日报） ...